Want to see TSE:RVV full AI Analyst Report?
Revive Therapeutics (RVV) Stock Statistics & Valuation Metrics
Total Valuation
Revive Therapeutics has a market cap or net worth of CAD 8.37M. The enterprise value is CAD 15.30M.
- Market Cap
- CAD 8.37M
- Enterprise Value
- CAD 15.30M
Share Statistics
Revive Therapeutics has 418,564,270 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 418,564,270
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Revive Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
- Return on Equity (ROE)
- ―
- Return on Assets (ROA)
- ―
- Return on Invested Capital (ROIC)
- ―
- Return on Capital Employed (ROCE)
- ―
- Revenue Per Employee
- 0
- Profits Per Employee
- -511.82K
- Employee Count
- 2
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Revive Therapeutics is -0.83. Revive Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.83
- PS Ratio
- 0.00
- PB Ratio
- -2.16
- Price to FCF
- -55.60
- Price to Operating Cash Flow
- -55.60
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Revive Therapeutics had revenue of 0 and earned -1.02M in profits. Earnings per share was -0.00.
- Revenue
- 0
- Gross Profit
- -189
- Operating Income
- -1.05M
- Pretax Income
- -1.02M
- Net Income
- -1.02M
- EBITDA
- -1.05M
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -156.71K and capital expenditures -4, giving a free cash flow of -156.71K billion.
- Operating Cash Flow
- -156.71K
- Free Cash Flow
- -156.71K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Revive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.80%
- Earnings Yield
- -121.92%
Stock Price Statistics
- Beta
- -1.35
- 52-Week Price Change
- 100.00%
- 50-Day Moving Average
- 0.02
- 200-Day Moving Average
- 0.03
- Relative Strength Index (RSI)
- 47.69
- Average Volume (3m)
- 197.11K
Important Dates
Revive Therapeutics upcoming earnings date is Nov 27, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Nov 27, 2026
- Ex-Dividend Date
- ―
Financial Position
Revive Therapeutics as a current ratio of 0.04, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.04
- Quick Ratio
- 0.04
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- ―
- Interest Coverage Ratio
- -91.54
Taxes
In the past 12 months, Revive Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Revive Therapeutics EV to EBITDA ratio is -0.82, with an EV/FCF ratio of -55.91.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.82
- EV to Free Cash Flow
- -55.91
- EV to Operating Cash Flow
- -55.91
Balance Sheet
Revive Therapeutics has CAD 22.66K in cash and marketable securities with CAD 70.77K in debt, giving a net cash position of -CAD 48.10K billion.
- Cash & Marketable Securities
- CAD 22.66K
- Total Debt
- CAD 70.77K
- Net Cash
- -CAD 48.10K
- Net Cash Per Share
- CAD 0.00
- Tangible Book Value Per Share
- -CAD 0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Revive Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 90.84%
Scores
- Smart Score
- ―
- AI Score
- 43